1. Home
  2. GTEC vs HCWB Comparison

GTEC vs HCWB Comparison

Compare GTEC & HCWB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Greenland Technologies Holding Corporation

GTEC

Greenland Technologies Holding Corporation

HOLD

Current Price

$1.05

Market Cap

13.4M

Sector

Industrials

ML Signal

HOLD

Logo HCW Biologics Inc.

HCWB

HCW Biologics Inc.

HOLD

Current Price

$2.24

Market Cap

5.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GTEC
HCWB
Founded
2006
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.4M
5.0M
IPO Year
2018
2021

Fundamental Metrics

Financial Performance
Metric
GTEC
HCWB
Price
$1.05
$2.24
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$35.00
AVG Volume (30 Days)
401.0K
163.1K
Earning Date
05-15-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.35
N/A
Revenue
$90,694,007.00
$4,099,750.00
Revenue This Year
$1.62
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$3.06
N/A
Revenue Growth
8.04
N/A
52 Week Low
$0.47
$0.25
52 Week High
$1.61
$6.11

Technical Indicators

Market Signals
Indicator
GTEC
HCWB
Relative Strength Index (RSI) 69.63 41.36
Support Level $0.96 $2.35
Resistance Level $1.16 $4.01
Average True Range (ATR) 0.08 0.38
MACD 0.01 -0.04
Stochastic Oscillator 69.34 21.59

Price Performance

Historical Comparison
GTEC
HCWB

About GTEC Greenland Technologies Holding Corporation

Greenland Technologies Holding Corp is a developer of quality solutions in the material handling industry. It is a transmission and drivetrain systems provider for material handling equipment such as forklift trucks for industrial and logistic applications. Geographically, the company has its presence in Domestic and International markets and earns majority of the revenue from Domestic Sales.

About HCWB HCW Biologics Inc.

HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.

Share on Social Networks: